Compare Microchip Technology Inc. (MCHP) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Novo Nordisk A/S — how do they compare? Microchip Technology Inc. trades at $74.32 (market cap $41.01B), while Novo Nordisk A/S trades at $38.53 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 4× Microchip Technology Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and Novo Nordisk A/S for 116 Days on average.
| MCHP | NVO | |
|---|---|---|
Market Cap | $41.01B | $165.31B |
Volume | 9,972,516 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $102.97 | $63.98 |
52-Week Low | $49.02 | $35.29 |
Typical Hold Time | 62 Days | 116 Days |
Enterprise Value | $46.13B | $179.56B |
Dividend Yield | 2.41% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $78.02, down 3.99% today, amid a bearish technical signal. The company shows mixed fundamentals with strong recent earnings beats but a challenging 2025 with negative net income. Valuation metrics appear elevated with P/E of 111.06 and P/S of 8.08. Recent developments include the acquisition of Hailo and expansion of Ethernet and power portfolios targeting automotive and data center markets.
Outlook remains cautiously optimistic with analyst consensus at $110.50 (41% upside) and no sell ratings. Key opportunities include AI infrastructure demand and inventory normalization, while risks include high debt levels, competitive pressures, and semiconductor cycle volatility. The stock's performance hinges on execution of growth initiatives and market conditions.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
